Loading
A phase 1/2 trial of Ivonescimab, Cadonilimab, Paclitaxel / nab-paclitaxel in pancreatic ductal adenocarcinoma, run by Akeso, active and no longer recruiting.
AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer is a phase 1/2 interventional study registered as NCT06646055 by Akeso, with 110 participants planned, started 2025-01-21 and due to reach its primary completion in 2026-12-30. Interventions recorded: AK112, Cadonilimab, nab-paclitaxel, gemcitabine, AK112, Cadonilimab, nab-paclitaxel, gemcitabine, AK112, Cadonilimab, nab-paclitaxel, gemcitabine, AK112, nab-paclitaxel, gemcitabine, nab-paclitaxel, gemcitabine. Conditions listed: Metastatic Pancreatic Ductal Adenocarcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Akeso, Ivonescimab, Bispecific antibodies, Gemcitabine.
Shares Cadonilimab, Akeso, Bispecific antibodies, Gemcitabine.
Shares Cadonilimab, Akeso, Ivonescimab, Bispecific antibodies.
Shares Cadonilimab, Akeso, Ivonescimab, Bispecific antibodies.
Shares Cadonilimab, Akeso, Bispecific antibodies, Immune checkpoint inhibitors.
Shares Cadonilimab, Akeso, Ivonescimab, Bispecific antibodies.
Shares Cadonilimab, Akeso, Bispecific antibodies, Paclitaxel / nab-paclitaxel.
Shares Cadonilimab, Akeso, Bispecific antibodies, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/